…ses manifesting thrombotic microangiopathy (TMA). Despite early Angiotensin-Converting Enzyme inhibitor (ACEi) intervention and glucocorticoid avoidance in high-risk SSc pati…
All extracted drugs
Showing 2,101–2,160 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Articles mentioning drugs
10,506 articles · page 502 of 876… progression were positivity for anti-topoisomerase-1 antibody (antiTOPO) compared to anti centromere (OR 3.20, 95%CI(1.17-9.65)), the p…
… (rs=0.47, 0.47, 0.47, and 0.42, respectively; all p<0.001) and HBcrAg (rs=0.57, 0.56, 0.57, and 0.44, respectively; all p<0.001). Fur…
…V-1 reservoir dynamics of HIV during treatment with long-acting cabotegravir and rilpivirine (LA CAB/RPV) remain limited. This study aimed t…
…e study included 25 PWH with metabolic complications prescribed semaglutide at the Modena HIV Metabolic Clinic, Italy, from January 2020 to…
…ge, duration of HIV infection, physical activity, INSTI, PI and statin use were included as covariates to weight relative risks of pro…
…involvement. Immunological variables comprised anti-centromere, Scl-70, and RNA polymerase III (anti-RNAP III) antibodies. Modified Ro…
…wing a progressive increase in skin from week-1 to week-4 after bleomycin treatment. ‘Proinflammatory fibroblasts’ were identified in bot…
…ssion, and recombinant protein treatments in vitro and in vivo (bleomycin (BLM)-induced murine fibrosis and keloid xenograft models). A d…
…r in patients with dcSSc, mainly with shorter disease duration. BRD4 may be a beneficial biomarker in patients with SSc, primarily f…
…WT) BALB/c mice, were used. All three strains were subjected to bleomycin (BLM) to induce scleroderma as the experimental groups, while W…
…M) and female (F) Ripk3iECKO and Ripk3WT mice were treated with tamoxifen at 8 weeks of age. At 12 weeks, mice were implanted with osmoti…